Abstract
The aim of this study was to evaluate the final stature of adults with childhood-onset steroid-responsive idiopathic nephrotic syndrome (INS) and the influence of disease-related issues on the achievement of their target heights. We analyzed 60 (41 male) patients and/or their records, with a minimum age of 19 years or at a Tanner’s pubertal stage 4 for boys or status postmenarche for girls, and normal glomerular filtration rate. Mean age at first and last consultation was 5.3 ± 2.4 years and 20.5 ± 3.1 years, respectively. Mean follow-up period was 15.10 years. Mean cumulative dose of prednisone was 1254 ± 831.40 mg/kg. Mean initial and final height Z scores (HtZ) were, respectively, −0.60 ± 1.0 and −0.64 ± 0.92 (p = 0.72). The final HtZ showed a significant correlation only with the initial HtZ and the target HtZ (THZ). Six patients achieved a final HtZ below −2, which in male patients correlated strongly to the initial HtZ and THZ. A strong correlation was demonstrated between final HtZ, initial HtZ, and THZ. INS-related issues did not prevent the final stature to reach the predicted target height.
Similar content being viewed by others
References
Eddy AA, Symond JM (2003) Nephrotic syndrome in childhood. Lancet 362:629–639
Crew RJ, Rashakrishnan J, Appel G (2004) Complications of the nephrotic syndrome and their treatment. Clin Nephrol 62:245–249
Donatti TL, Koch VH, Fujimura MD, Okay Y (2003) Growth in steroid-responsive nephrotic syndrome: a study of 85 pediatric patients. Pediatr Nephrol 18:789–795
Tanner JM, Goldstein H, Whitehouse RH (1970) Standards for children’s height at ages 2–9 years allowing for height of parents. Arch Dis Child 45:755–762
WHO Multicentre Growth Reference Study Group (2006) WHO Child Growth Standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. World Health Organization, Geneva, p 312
Lam CN, Arneil GC (1968) Long-term dwarfism effects of corticosteroid treatment for childhood nephrosis. Arch Dis Child 43:589–594
Polito C, Oporto MR, Totino SF, La Manna A (1986) Normal growth of nephrotic children during long-term alternate-day prednisone therapy. Acta Paediatr Scand 75:245–250
Sadeghi-Nejad A, Senior B (1969) Adrenal function, growth, and insulin in patients treated with corticoids on alternate days. Pediatrics 43:277–283
Saha MT, Laippala P, Lenko HL (1998) Normal growth of prepubertal nephrotic children during long-term treatment with repeated courses of prednisone. Acta Paediatr 87:545–548
Centers for Disease Control and Prevention, CDC growth charts. Available at www.cdc.gov/growthcharts. Accessed June 9, 2009
Must A, Dallal GE, Dietz WH (1991) Reference data for obesity: 85th and 95th percentiles of body mass index (Wt/Ht2) and triceps skinfold thickness. Am J Clin Nutr 53:839–846
Tanner JM (1986) The use and abuse of growth standards. In: Falkner F, Tanner JM (eds) Human growth, 2nd edn. Plenum, New York, pp 95–112
Rosner B (1995) Fundamentals of biostatistics, 4th edn. Duxbury, New York
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
International Study of Kidney Disease in Children (ISKDC) (1981) The primary nephrotic syndrome in children: identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 98:561–564
International Study of Kidney Disease in Children (ISKDC) (1978) Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics time of diagnosis. Kidney Int 13:159–165
Ruth EM, Kemper MJ, Leumann EP, Laube GF, Thomas J, Neuhaus TJ (2005) Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr 147:202–207
Martinelli CE Jr, Moreira AC (1994) Relation between growth hormone and cortisol spontaneous secretion in children. Clin Endocrinol (Oxf) 41:117–121
Senaris RM, Lago F, Coya R, Pineda J, Dieguez C (1996) Regulation of hypothalamic somatostatin, growth hormone-releasing hormone, and growth hormone receptor messenger ribonucleic acid by glucocorticoids. Endocrinology 137:5236–5241
Malerba M, Bossoni S, Radaeli A, Mori E, Bonadonna S, Giustina A, Tantucci C (2005) Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment. Chest 127:515–521
Iwasaki Y, Morishita M, Asai M, Onishi A, Yoshida M, Oiso Y, Inoue K (2004) Effects of hormones targeting nuclear receptors on transcriptional regulation of the growth hormone gene in the MtT/S rat somatotrope cell line. Neuroendocrinology 79:229–236
Gafni RI, Weise M, Robrecht DT, Meyers JL, Barnes KM, De-Levi S, Baron J (2001) Catch-up growth is associated with delayed senescence of the growth plate in rabbits. Pediatr Res 50:618–623
Elders M, Wingfield BS, McNatt ML, Clarke JS, Hughes ER (1975) Glucocorticoid therapy in children. Am J Dis Child 129:1393–1396
Baron J, Klein KO, Colli MJ, Yanovski JA, Novosad JA, Bacher JD, Cutler GB Jr (1994) Catch-up growth after glucocorticoid excess: a mechanism intrinsic to the growth plate. Endocrinology 135:1367–1371
Gafni RI, Baron J (2000) Catch-up growth: possible mechanisms. Pediatr Nephrol 14:616–619
Tanner JM (1994) Auxology. In: Kappy MS, Blizzard RM, Migeon CJ (eds) The diagnosis and treatment of endocrine disorders. Charles C. Thomas, Springfield, pp 137–192
Rees L, Greene SA, Adlard P, Jones J, Haycock GB, Rigden SPA, Preece M, Chantler C (1988) Growth and endocrine function in steroid sensitive nephrotic syndrome. Arch Dis Child 63:484–490
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Donatti, T.L., Koch, V.H. Final height of adults with childhood-onset steroid-responsive idiopathic nephrotic syndrome. Pediatr Nephrol 24, 2401–2408 (2009). https://doi.org/10.1007/s00467-009-1301-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-009-1301-z